All In Biotech

Drug Trial Radar · NCT04683250

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

244

Planned (sponsor's estimate)

Start

Dec 16, 2020

Primary completion

Mar 2030

Study completion Mar 2031

Sponsor

Lead sponsor
Taiho Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.

Conditions

  • RET-altered Non Small Cell Lung Cancer
  • RET-altered Solid Tumors

Interventions

  • TAS0953/HM06Drug

    Phase 1: oral, starting dose 20mg twice a day, until recommended phase 2 dose, continuous daily dosing, cycles lasting 21 days

  • TAS0953/HM06Drug

    Phase 2: oral, recommended dose twice a day, continuous daily dosing, cycles lasting 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 (dose-escalation): Maximum Tolerated Dose (MTD)Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Phase 1 (dose-expansion): Recommended Phase 2 dose (RP2D)Time frame: At the end of Cycle 1 (each cycle is 21 days), and at the end of every subsequent cycle (each cycle is 21 days) for approximately 10 months (or earlier if patient discontinues the study)
  3. Phase 2: Objective Response Rate (ORR) by independent central reviewTime frame: Approximately every 6 weeks for 6 months, then every 9 weeks during treatment, 7 days after the last dose, and every 3 months after the last dose (up to an average of 2 years) in patients without progressive disease.

Locations

29 sites in 4 countries. Site status is shown where the registry gives one.

  • Chao Family Comprehensive Cancer Center

    Orange, California · Terminated

  • Stanford Cancer Center

    Stanford, California · Terminated

  • Massachusetts General Hospital

    Boston, Massachusetts · Terminated

  • Henry Ford Hospital

    Detroit, Michigan · Terminated

  • START Midwest - Cancer & Hematology Centers of Western Michigan

    Grand Rapids, Michigan · Terminated

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Terminated

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Terminated

  • The Sarah Cannon Research Institute/Tennessee Oncology

    Nashville, Tennessee · Terminated

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas · Terminated

  • Cabrini Hospital

    Malvern, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Australia · Recruiting

  • GenesisCare North Shore

    Saint Leonards, Australia · Recruiting

  • Aichi Cancer Center

    Aichi, Japan · Recruiting

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Japan · Recruiting

  • Kanagawa Cancer Center

    Kanagawa, Japan · Recruiting

  • Kurashiki Central Hospital

    Okayama, Japan · Recruiting

  • Kindai University Hospital

    Osaka, Japan · Recruiting

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, Japan · Recruiting

  • Tohoku University Hospital

    Sendai, Miyagi, Japan · Recruiting

  • Okayama University Hospital

    Okayama, Okayama-ken, Japan · Recruiting

  • Kansai Medical University Hospital

    Hirakata-shi, Osaka, Japan · Recruiting

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan · Recruiting

  • Shizuoka Cancer Center

    Shizuoka, Shizuoka, Japan · Recruiting

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan · Recruiting

  • The Cancer Institute Hospital of JFCR

    Koto-ku, Tokyo, Japan · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.